Go Unlimited with Magzter GOLD
Get unlimited access to 10,000+ magazines, newspapers and Premium stories for just
Try GOLD - Free
US generics, domestic market to drive pharma cos' Q4 sales growth
Mint New Delhi
|April 29, 2025
Analysts anticipate higher sales of Revlimid to drive growth for US-focused firms such as Sun Pharma in Q4
Pharma companies are expected to report healthy revenue growth of 11-13% in the fourth quarter of FY25, driven by strong traction in niche US generic drugs, steady domestic performance in a seasonally weak quarter and higher sales of a blockbuster cancer drug in the US before its distribution exclusivity ends next year, analysts said.
Uncertainties over US tariffs and the end of the limited competition period for generic Revlimid in the US loom in the months ahead. However, analysts anticipate higher sales of Revlimid to drive growth for US-focused companies such as Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd and Sun Pharmaceutical Industries Ltd in Q4 and the first few quarters of the next fiscal.
This story is from the April 29, 2025 edition of Mint New Delhi.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Mint New Delhi
Mint New Delhi
E-gold firms seek regulatory cover
Digital gold companies may ask the union government to approve their plans for self-regulation if the Securities and Exchange Board of India (Sebi) refuses to regulate the instrument, said a top executive at the India Bullion and Jewellery Association (IBJA), the apex body for all bullion and jewellery associations in India.
3 mins
November 20, 2025
Mint New Delhi
Red Fort blast: Can tech bolster India's security?
The 10 November suicide bombing in the heart of Delhi has raised concerns about public safety in crowded hubs across India. While agencies pursue the perpetrators, police are sharpening their ability to detect security gaps, and fortify defences. Mint looks at the measures.
2 mins
November 20, 2025
Mint New Delhi
How high credit card utilization affects your score: a quick guide
I had a ₹1 lakh credit card bill but repaid ₹40,000; ₹60.000 is due. Will it hurt my credit score? Can I take a personal loan to clear it? Will it affect my score and future loan applications? - Name withheld on request
1 mins
November 20, 2025
Mint New Delhi
Incentives drive each and every participant in all capital markets
Investors must note that everyone is motivated by self-interest whether we know the specifics or not
4 mins
November 20, 2025
Mint New Delhi
India's financial boom: Let's keep progress real
Record funds raised for shareholder exits rather than fresh investment go against the spirit of IPOs. The bigger issue is that the financial world must stay in sync with the real economy
2 mins
November 20, 2025
Mint New Delhi
India Inc's rural engine sputters in Sep quarter
Tepid farm income, sluggish credit growth and an uneven consumption recovery weighed on the momentum of companies linked to rural India in the September quarter, pulling back their pace of growth, even as they stayed ahead of the non-rural pack on some key parameters, a Mint analysis showed.
3 mins
November 20, 2025
Mint New Delhi
Meta's big court win
Social media major Meta has won big relief as a US judge ruled in its favour in an antitrust case filed by the US Federal Trade Commission (FTC) that could have forced it to spin off Instagram and WhatsApp.
1 min
November 20, 2025
Mint New Delhi
xAI in talks to raise $15 billion in fresh equity
Elon Musk's artificial-intelligence startup xAI is in advanced talks to raise $15 billion in fresh equity at a valuation of $230 billion, The Wall Street Journal reported on Tuesday.
1 min
November 20, 2025
Mint New Delhi
AYURVEDIC HOSPITAL CARE: WHY INSURERS PUSH BACK—AND HOW TO WIN CLAIMS
Over the past few years, a friend has undergone Ayurvedic treatment for fluctuating blood pressure at a Kerala hospital. The insurer had routinely covered a week of hospitalization, but this time rejected the claim, arguing the annual treatment appeared more like rest than medical necessity. Ayurvedic claims are becoming harder to get approved.
3 mins
November 20, 2025
Mint New Delhi
Fabindia-Biome row now in arbitration
The founders of personal care company Biome Life Sciences India Pvt. Ltd on Wednesday told the Delhi high court that they were withdrawing their petition against parent Fabindia Ltd over share valuations.
2 mins
November 20, 2025
Listen
Translate
Change font size